CA-AGENDIA
Agendia, Inc. , a world leader in precision oncology for breast cancer, today shared data demonstrating the ability of MammaPrint® and BluePrint® to predict patient outcomes following neoadjuvant chemotherapy (NAC) at the 2021 San Antonio Breast Cancer Symposium (SABCS 2021).
The poster, titled MammaPrint and BluePrint are prognostic of outcome following neoadjuvant chemotherapy , presents findings that indicate MammaPrint and BluePrint accurately correlated with chemosensitivity and outcomes in NAC-treated patients. The research was conducted in collaboration with Cedars-Sinai Medical Center.
Notably, approximately 1 in 4 tumors which were MammaPrint High Risk (Luminal B) prior to NAC became MammaPrint Low Risk (Luminal A) when the post-treatment tissue was analyzed. Patients with reclassified MammaPrint Low Risk tumors had improved five-year outcomes compared to patients that remained High Risk after treatment. These data signal a role for serial genomic testing to determine proper classification of breast cancer tumors following NAC treatment in order to appropriately manage a woman’s future treatment plan and prognosis.
“By analyzing MammaPrint and BluePrint on pre- and post-NAC tissue samples for those with residual disease, we unlock new insights about their clinical utility and potential impact on treatment decisions given the biological changes that may occur following initial intervention,” said Alice P. Chung, MD, Division of Surgical Oncology, Department of Surgery, Cedars-Sinai Medical Center. “The importance of accurate genomic classification of a tumor is crucial, especially in the context of these findings where 1 in 4 High Risk tumors became Low Risk – insights which can significantly affect our treatment planning discussions with patients.”
The analysis presented at SABCS 2021 features data from 128 women (median age 50) with stage I-III early breast cancer (EBC), of any clinical subtype, diagnosed from 2007-2016 who received NAC at Cedars-Sinai Medical Center. Among 111 pre-treated tumors, MammaPrint High Risk tumors had a significantly higher pathological complete response (pCR) rate than Low Risk tumors. Amongst tumors that had discordant MammaPrint results between pre- and post-treatment samples, the only change observed was from High Risk to Low Risk. BluePrint results were very consistent between pre- and post-NAC samples (92% concordance) with reclassification only occurring in the HER2-Type cohort, consistent with the known heterogeneity in clinically HER2-positive tumors.
“Neoadjuvant chemotherapy is the standard of care for the initial treatment of certain types of breast cancer, and for many women, the clinical response to therapy is thought to carry prognostic implications. This study illustrates the additional information provided by our genomic assays regarding response to therapy and prognosis,” said William Audeh, MD, Chief Medical Officer at Agendia and a study author. “While changes in the MammaPrint Risk index with treatment are clearly associated with outcome, it is also important to note the consistency of BluePrint results pre- and post- treatment with neoadjuvant chemotherapy. These data further demonstrate the prognostic accuracy of the assays and confirm the importance of genomic information in our quest to identify better biomarkers in patients treated with neoadjuvant chemotherapy.”
Future studies will study the effect of NAC on the breast cancer transcriptome and its association with clinical outcomes.
About Agendia
Agendia is a mission-driven company focused on enabling optimized treatment planning by providing physicians with next-generation diagnostic and information solutions that can be used to help improve outcomes and quality of life for breast cancer patients worldwide. The company currently offers two commercially-available genomic profiling tests that help surgeons, oncologists and pathologists to personalize treatment for women at critical intervention points throughout their patient journey.
MammaPrint® is a 70-gene prognostic test that, along with other clinicopathologic factors, determines a specific patient’s breast cancer recurrence risk. BluePrint® is an 80-gene molecular subtyping test that identifies the underlying biology of an individual breast cancer to provide information about its behavior, long-term prognosis and potential response to systemic therapy. Together, MammaPrint® and BluePrint® provide a holistic view of an individual patient’s breast cancer, enabling physicians to objectively select the best treatment plan.
For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211209006022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Crown Bioscience San Diego Laboratory Achieves CAP Accreditation, Building on CLIA Certification to Expand Clinical-Grade Capabilities20.1.2026 14:30:00 CET | Press release
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced that its San Diego laboratory has achieved College of American Pathologists (CAP) accreditation. This milestone builds on the site’s Clinical Laboratory Improvement Amendments (CLIA) certification, obtained in July 2025, further strengthening its ability to deliver clinical-grade biomarker testing to support regulated drug development programs. CAP accreditation is recognized as a leading benchmark for laboratory quality, reflecting rigorous standards for operational excellence, technical competence, and quality oversight. Together with CLIA certification—regulated by the U.S. Centers for Medicare & Medicaid Services—these credentials confirm the San Diego laboratory’s compliance with federal requirements for clinical testing on human specimens and its readiness to support biomarker analyses aligned with clinical trial and regulatory expectations. “Achieving CAP accreditatio
Leon and SkyAccess Announce Official Integration to Automate Empty Leg Listings for Charter Operators Across Europe20.1.2026 14:24:00 CET | Press release
SkyAccess, a real-time empty leg flight marketplace that aggregates private jet repositioning flights from a network of certified operators, and Leon Software, a cloud-based aviation management software platform used by charter operators worldwide, today announced an official integration that enables Leon charter operators to automatically list eligible empty leg and repositioning flights on the SkyAccess empty-leg marketplace. Meeting Growing Demand for Empty Leg Flights in Europe The announcement comes as interest in empty leg flights continues to grow across Europe, particularly on short-haul routes between major business and leisure hubs. Travelers are increasingly seeking flexible, one-way private jet options and more transparent access to repositioning flights. “Empty legs move quickly, and speed matters,” said Paweł Szmagaj, CTO of Leon Software. “With the Leon Software–SkyAccess integration, operators can share up-to-date availability with the market faster, while maintaining f
Colgate-Palmolive and WHO Foundation Announce Global Partnership on Oral Health20.1.2026 14:00:00 CET | Press release
Multi-year funding will advance oral health, as oral diseases are among the most prevalent and overlooked noncommunicable diseases impacting 3.7 billion people globally.1 Today, Colgate-Palmolive announced a new multi-year collaboration with the WHO Foundation to support the World Health Organization's work on oral health. The four-year funding commitment will help expand oral health education, support integration of oral health into national health systems, and raise awareness of oral health as a public health priority. This initiative builds on Colgate’s commitment to providing communities with oral health education and resources. The Company recently announced that the Colgate Bright Smiles, Bright Futures® program has reached approximately two billion children and their families around the world since 1991 with oral health education. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260120050760/en/ “At Colgate-Palmolive, w
FGS Global Launches AI Advisory Practice and Acquires Threat Intelligence Firm Memetica20.1.2026 14:00:00 CET | Press release
Dedicated global practice to help organizations navigate and optimize AI comms transformationAI-driven threat intelligence offer identifies, assesses and mitigates emerging risks across the dark web FGS Global, the world's leading stakeholder strategy firm, today announced the launch of its AI Advisory practice and the acquisition of Memetica, a specialist technology consultancy in AI-driven threat detection and mitigation across social, dark web and fringe platforms. The new practice sits within FGS Global's recently formed AI and Innovation group led by Aaron Kwittken, Global Head of AI and Innovation. The AI Advisory practice builds on and consolidates FGS Global's deliberate, years-long investment in AI capabilities to support surging client demand for strategic and practical guidance on leveraging AI and emerging technologies to enhance communications efficacy, reputational defense and operational efficiencies. This critical work is supported by a global team of more than 200 stra
KnowBe4 Honored for Global Employee Experience Across Multiple Workplace Awards20.1.2026 14:00:00 CET | Press release
Recognized across 11 countries with certifications from Great Place to Work®, Computerworld, Top Workplaces, and America's Most Loved Workplaces® KnowBe4, the world-renowned platform that comprehensively addresses human and agentic AI risk management, today announced it has earned several prestigious workplace awards in Q4 2025. These include Great Place to Work® Certifications across 11 countries, recognition on Computerworld's 2026 Best Places to Work in IT list, and honors from Top Workplaces and America's Most Loved Workplaces®. The awards recognize KnowBe4's ongoing commitment to fostering an exceptional workplace culture that empowers employees to thrive both professionally and personally. "This recognition belongs to every single member of our KnowBe4 team," said Ani Banerjee, chief human resources officer at KnowBe4. "These awards validate our commitment to creating a workplace where people truly want to come to work each day. When employees feel valued and empowered, remarkabl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom